Roche's strategy of expanding Gazyva across kidney-immunology diseases (lupus, membranous nephropathy) demonstrates scalable growth potential through existing biologics. - At 16x earnings with 3% ...
JAKARTA, INDONESIA AND DANVILLE, CA, Sept. 25, 2026 (GLOBE NEWSWIRE) -- (NYSE American: INDO) ("IEC"), an oil and gas exploration and production company focused on Indonesia, today announced, in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results